Related references
Note: Only part of the references are listed.Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients With Psychotic Disorders Compared to Patients With Nonpsychotic Disorders or No Psychiatric Disorders Results From a 12-month, Real-World Study
Jian-Ping Zhang et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2012)
Pharmacogenetics in psychiatry: translating research into clinical practice
A. K. Malhotra et al.
MOLECULAR PSYCHIATRY (2012)
Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications
T. A. P. Lett et al.
MOLECULAR PSYCHIATRY (2012)
Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain
D. J. Mueller et al.
PHARMACOGENOMICS JOURNAL (2012)
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction
Jian-Ping Zhang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Candidate Gene Analysis Identifies a Polymorphism in HLA-DQB1 Associated With Clozapine-Induced Agranulocytosis
Maria C. Athanasiou et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs
D. E. Adkins et al.
MOLECULAR PSYCHIATRY (2011)
D2 Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis
Jian-Ping Zhang et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Personalized Medicine for Depression: Can We Match Patients With Treatments?
Gregory E. Simon et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment
Chen-Jee Hong et al.
PHARMACOGENETICS AND GENOMICS (2010)
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia
Todd Lencz et al.
PHARMACOGENETICS AND GENOMICS (2010)
Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis
Michelle N. Sicard et al.
PHARMACOGENOMICS (2010)
Metabolic syndrome with the atypical antipsychotics
Pornpoj Pramyothin et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2010)
Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden
Frida Renstrom et al.
HUMAN MOLECULAR GENETICS (2009)
Applicability of a Genetic Signature for Enhanced Iloperidone Efficacy in the Treatment of Schizophrenia
Simona Volpi et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Medication Adherence: A Review of the Literature and Implications for Clinical Practice
Rose J. Julius et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2009)
Olanzapine-induced weight gain is associated with the-759C/T and-697G/C polymorphisms of the HTR2C gene
B. R. Godlewska et al.
PHARMACOGENOMICS JOURNAL (2009)
G-protein β3 Subunit Gene 82SC/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients
Young-Min Park et al.
PSYCHIATRY INVESTIGATION (2009)
Lack of association between the-759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients
Y. -M. Park et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2008)
Association of antipsychotic induced weight gain and body mass index with GNB3 gene: A meta-analysis
Renan P. Souza et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens
M. Dettling et al.
PHARMACOGENOMICS JOURNAL (2007)
-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment
Seunghyong Ryu et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2007)
Genomics and the future of pharmacotherapy in psychiatry
Anil K. Malhotra et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2007)
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
JP McEvoy et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Drug-induced agranulocytosis -: Impact of different Fcγ receptor polymorphisms?
I Mosyagin et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
JA Lieberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pharmacogenetics-based therapeutic recommendations -: ready for clinical practice?
J Kirchheiner et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Weight gain associated with the-759 C/T polymorphism of the 5HT2C receptor and olanzapine
VL Ellingrod et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2005)
Clozapine-induced weight gain associated with the 5HT2C receptor-759C/T polymorphism
DD Miller et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2005)
Lack of association between the-759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals
FM Theisen et al.
PSYCHIATRIC GENETICS (2004)
Pharmacogenetics of antipsychotic-induced weight gain
CU Correll et al.
PSYCHOPHARMACOLOGY (2004)
Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis
I Mosyagin et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2004)
NQO2 gene is associated with clozapine-induced agranulocytosis
O Ostrousky et al.
TISSUE ANTIGENS (2003)
-759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain
SJ Tsai et al.
LANCET (2002)
Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism
GP Reynolds et al.
LANCET (2002)
Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry
M Dettling et al.
PHARMACOGENETICS (2001)
Genetic determinants of clozapine-induced agranulocytosis: Recent results of HLA subtyping in a non-Jewish Caucasian sample
M Dettling et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes:: No association with myeloperoxidase and cytochrome P450206
M Dettling et al.
PHARMACOPSYCHIATRY (2000)
Share Paper
